Antiviral activity of Bifidobacterium adolescentis SPM0212 against Hepatitis B virus

Archives of Pharmacal Research

Volumn 36, Issue 12, 2013, Pages 1525-1532

  Lee, Do Kyung ^a   Kang, Joo Yeon ^b   Shin, Hea Soon ^b   Park, Il Ho ^a   Ha, Nam Joo ^a  

^a Sahmyook University   (South Korea)

^b Duksung Women's University   (South Korea)

Author keywords

Antiviral activity; Bifidobacterium adolescentis; Hepatitis B virus; HepG2.2.15; Interferon; Probiotics

Indexed keywords

CELL EXTRACT; GUANOSINE TRIPHOSPHATASE; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; MYXOVIRUS RESISTANCE PROTEIN A;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; BACTERIUM ISOLATION; BIFIDOBACTERIUM ADOLESCENTIS; CELL STRAIN HEPG2; CONTROLLED STUDY; CULTURE MEDIUM; DRUG CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HEPATITIS B VIRUS; HUMAN; KOREA; MALE; MOLECULAR WEIGHT; NONHUMAN; NORMAL HUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS INHIBITION; VIRUS REPLICATION;

ADULT; ANIMALS; ANTIVIRAL AGENTS; BIFIDOBACTERIUM; DNA, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; MALE; PROBIOTICS; SHEEP; YOUNG ADULT;

EID: 84890796799     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-013-0141-3     Document Type: Article

References (40)

1. Andersson, I., L. Bladh, M. Mousavi-Jazi, K.E. Maqnusson, A. Lundkvist, O. Haller, and A. Mirazimi. 2004. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. Journal of Virology 78: 4323-4329. (Pubitemid 38437235)
2. Arase, Y., K. Ikeda, F. Suzuki, Y. Suzuki, S. Saitoh, M. Kobayashi, N. Akuta, T. Somey, T. Hosaka, H. Sezaki, M. Kobayashi, and H. Kumada. 2006. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. American Journal of Medicine 119: 71.e9-16. (Pubitemid 43117476)
3. Buti, M., and R. Esteban. 2005. Drugs in development for hepatitis B. Drugs 65: 1451-1460. (Pubitemid 41124302)
4. Cha, M.K., D.K. Lee, H.M. An, S.W. Lee, S.H. Shin, J.H. Kwon, and K.J. Kim. 2012. Antiviral activity of Bifidobacterium adolescentis SPM 1005-A on human papillomavirus type 16. BMC Medicine 10: 72. doi: 10.1186/1741-7015-10-72.
5. Chen, C.H., C.M. Lee, J.H. Wang, H.D. Tung, C.H. Hung, and S.N. Lu. 2004. Correlation of quantitative assay of hepatitis B surface antigen and HBV DNA levels in asymptomatic hepatitis B virus carriers. European Journal of Gastroenterology and Hepatology 16: 1213-1218. (Pubitemid 39488796)
6. Chieux, V., W. Chehadeh, J. Harvev, O. Haller, P. Wattre, and D. Hober. 2001. Inhibition of coxsackievirus B4 replication in stably transfected cells expressing human MxA protein. Virology 283: 84-92. (Pubitemid 32911512)
7. Cho, Y.K., and B.C. Song. 2011. New insight for HBV DNA HBsAg quantitation during antiviral therapy in patients with chronic hepatitis B. Korean Journal of Gastroenterology 57: 144-149.
8. De Santis, A., G. Famularo, and C. De Simone. 2000. Probiotics for the hemodynamic alterations of patients with liver cirrhosis. American Journal of Gastroenterology 95: 323-324.
9. Gill, H.S., and F. Guarner. 2004. Probiotics and human health: a clinical perspective. Postgraduate Medical Journal 80: 516-526. (Pubitemid 39265294)
10. Gordien, E., O. Rosmorduc, C. Peltekian, F. Garreau, C. Brechot, and D. Kremsdorf. 2001. Inhinbition of hepatitis B virus replication by the interferon-inducible MxA protein. Journal of Virology 75: 2684-2691. (Pubitemid 32185032)
11. Han, S.H., K.H. Cho, C.K. Lee, Y.C. Song, S.H. Park, N.J. Ha, and K.J. Kim. 2005a. Enhancement of antigen presentation capability of dendritic cells and activation of macrophages by the components of Bifidobacterium pseudocatenulatum SPM1204. Journal of Applied Pharmacology 13: 174-180.
12. Han, S.Y., C.S. Huh, Y.T. Ahn, K.S. Lim, Y.J. Baek, and D.H. Kim. 2005b. Hepatoprotective effect of lactic acid bacteria. Journal of Microbiology and Biotechnology 15: 887-890.
13. Iloeje, U.H., H.I. Yang, C.L. Jen, J. Su, L.Y. Wang, S.L. You, and C.J. Chen. 2007. Risk and predictors of mortality associated with chronic hepatitis B infection. Clinical Gastroenterology and Hepatology 5: 921-931. (Pubitemid 47161142)
14. Im, S.J., and Y.C. Sung. 2006. Action mechanism in immunopathogenesis and clearance of HBV. Korean Journal of Gastroenterology 12: 154-162.
15. Jansen, R.W., L.C. Johnson, and D.R. Averett. 1993. High-capacity in vitro assessment of anti-hepatitis B virus compound selectivity by a virion-specific polymerase chain reaction assay. Antimicrobial Agents and Chemotherapy 37: 441-447. (Pubitemid 23072586)
16. Jia, F., Y.Z. Zhang, and C.M. Liu. 2007. Stable inhibition of hepatitis B virus expression and replication in HeptG2.2.15 cells by RNA interference based on retrovirus delivery. Journal of Biotechnology 128: 32-40. (Pubitemid 46001687)
17. Kao, J.H., and D.S. Chen. 2002. Global control of hepatitis B virus infection. Lancet Infectious Diseases 2: 395-403. (Pubitemid 34693257)
18. Kim, B.K., S.Y. Kwon, C.H. Lee, W.H. Choe, H.M. Choi, and H.W. Koo. 2009. Analysis of the cost-effectiveness of antiviral therapies in chronic hepatitis B patients in Korea. Korean Journal of Gastroenterology 15: 25-41.
19. Korba, B.E., and G. Milman. 1991. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Research 15: 217-228.
20. Kruining, J., R.A. Heijtink, and S.W. Schalm. 1995. Antiviral agents in hepatitis B virus transfected cell lines: inhibitory and cytotoxic effect related to time of treatment. Journal of Hepatology 22: 263-267.
21. Lavanchy, D. 2004. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 11: 97-107. (Pubitemid 38365759)
22. Lee, D.K., S. Jang, E.H. Baek, M.J. Kim, K.S. Lee, H.S. Shin, M.J. Chung, J.E. Kim, and K.O. Lee. 2009a. Lactic acid bacteria affect serum cholesterol levels, harmful fecal enzyme activity, and fecal water content. Lipids in Health and Disease 8: 21. doi: 10.1186/1476-511X-8-21.
23. Lee, Y.H., L.J. Kang, and S.G. Lee. 2009b. Nelumbo nucifera leaves extract reduced the production of hepatitis B surface antigen on HepG2.2.15. Korean Journal of Medicinal Crop Science 17: 133-138.
24. Lee, D.K., S. Jang, M.J. Kim, J.H. Kim, M.J. Chung, K.J. Kim, and N.J. Ha. 2008. Anti-proliferative effects of Bifidobacterium adolescentis SPM0212 extract on human colon cancer cell lines. BMC Cancer 8: 310. doi: 10.1186/1471-2407-8-310.
25. Lee, D.K., S.Y. Park, S. Jang, E.H. Baek, M.J. Kim, S.M. Huh, K.S. Choi, M.J. Chung, J.E. Kim, K.O. Lee, and N.J. Ha. 2011. The combination of mixed lactic acid bacteria and dietary fiber lowers serum cholesterol levels and fecal harmful enzyme activities in rats. Archives of Pharmacal Research 34: 23-29.
26. Lin, Y.L., M.S. Shiao, C. Mettling, and C.K. Chou. 2003. Cholesterol requirement of hepatitis B surface antigen (HBsAg) secretion. Virology 314: 253-260. (Pubitemid 37158013)
27. -ΔΔCT method. Methods 25: 402-408. (Pubitemid 34164012)
28. Miettinen, M., J. Vuopio-Varkila, and K. Varkila. 1996. Production of human tumor necrosis factor alpha, interleukin-6, and interleukin-10 is induced by lactic acid bacteria. Infection and Immunity 64: 5403-5405. (Pubitemid 26404010)
29. Nosova, T., H. Jousimies-Somer, K. Jokelainen, R. Hein, and M. Salaspuro. 2000. Acetaldehyde production and metabolism by human indigenous and probiotic Lactobacillus and Bifidobacterium strains. Alcohol and Alcoholism 35: 561-568.
30. Parvez, S., K.A. Malik, S. Ah Kang, and H.Y. Kim. 2006. Probiotics and their fermented food products are beneficial for health. Journal of Applied Microbiology 100: 1171-1185. (Pubitemid 43739184)
31. Perrillo, R.P. 2005. Current treatment of chronic hepatitis B: benefits and limitations. Seminars in Liver Disease 25: 20-28. (Pubitemid 41254590)
32. Sadler, A.J., and B.R. Williams. 2008. Interferon-inducible antiviral effectors. Nature Reviews Immunology 8: 559-568. (Pubitemid 351913674)
33. Sells, M.A., M.L. Chen, and G. Acs. 1987. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proceedings of the National Academy of Sciences of the United States of America 84: 1005-1009. (Pubitemid 17031557)
34. Shin, H.S., S.Y. Park, D.K. Lee, S.A. Kim, H.M. An, J.R. Kim, M.J. Kim, M.G. Cha, S.W. Lee, K.J. Kim, K.O. Lee, and N.J. Ha. 2010. Hypocholesterolemic effect of sonication-killed Bifidobacterium longum isolated from healthy adult Koreans in high cholesterol fed rats. Archives of Pharmacal Research 33: 1425-1431.
35. Solga, S.F. 2003. Probiotics can treat hepatic encephalopathy. Medical Hypotheses 61: 307-313. (Pubitemid 36976202)
36. Strober, W. (2001) Trypan blue exclusion test of cell viability. Current Protocols in Immunology, Appendix 3, Appendix 3B doi: 10.1002/0471142735. ima03bs21.
37. Su, T.H., C.S. Hsu, C.L. Chen, C.H. Liu, Y.W. Huang, T.C. Tseng, C.J. Liu, P.J. Chen, M.Y. Lai, D.S. Chen, and J.H. Kao. 2010. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antiviral Therapy 15: 1133-1139.
38. Wang, G.F., L.P. Shi, Y.D. Ren, Q.F. Liu, H.F. Liu, R.J. Zhang, Z. Li, F.H. Zhu, P.L. He, W. Tang, P.Z. Tao, C. Li, W.M. Zhao, and J.P. Zuo. 2009. Anti-hepatitis B virus activity of chlorogenic acid, quinic acid and caffeic acid in vivo and in vitro. Antiviral Research 83: 186-190.
39. Yuen, M.F., D.K. Wong, E. Sablon, E. Tse, I.O. Ng, H.J. Yuan, C.W. Siu, T.J. Sander, E.J. Bourne, J.G. Hall, L.D. Condreay, and C.L. Lai. 2004. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological and clinical aspects. Hepatology 39: 1694-1701. (Pubitemid 38702671)
40. Zhao, R., T.Z. Wang, D. Kong, L. Zhang, H.X. Meng, Y. Jiang, Y.Q. Wu, Z.X. Yu, and X.M. Jin. 2011. Hepatoma cell line HepG2.2.15 demonstrates distinct biological features compared with parental HepG2. World Journal of Gastroenterology 17: 1152-1159.